Beta Bionics, Inc. (BBNX) stock
Close on Nov 17, 2026Market cap $800.28MP/E –Yield –
Earnings
Beta Bionics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Beta Bionics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 16, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 27, 2026after the close | $35.50M | +30.0% | -$0.52 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 29, 2026after the close | $32.00M | +37.9% | – | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 21, 2026after the close | $27.60M | +56.8% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 17, 2026after the close | $32.10M | +57.4% | -$0.30 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 28, 2025after the close | $27.30M | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 29, 2025after the close | $23.20M | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025after the close | $17.60M | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 25, 2025after the close | $20.40M | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Beta Bionics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| total revenue | FY2026 | $124.00M – $126.00M | $130.00M – $135.00M | Lowered | Oct 27, 2026 |
| total revenue | FY2026 | $131.00M – $136.00M | $131.00M – $136.00M | Reaffirmed | Jul 29, 2026 |
| gross margin | FY2026 | 58.5% – 59.5% | 55.5% – 57.5% | Raised | Oct 27, 2026 |
| gross margin | FY2026 | 58.5% – 59.5% | 57.5% – 59.5% | Raised | Jul 29, 2026 |
| new patient starts reimbursed through the PBP channel | FY2026 | 37% – 39% | 36% – 38% | Raised | Oct 27, 2026 |
| new patient starts reimbursed through the PBP channel | FY2026 | 37% – 39% | 37% – 39% | Reaffirmed | Jul 29, 2026 |
Guidance vs results
The last range Beta Bionics gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $96.50M | $100.20MΣ4Q | Above range |
Guidance history
Every forecast Beta Bionics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 27, 2026 | gross margin | FY2026 | 58.5% – 59.5% | Raised |
| Oct 27, 2026 | new patient starts reimbursed through the PBP channel | FY2026 | 37% – 39% | Raised |
| Oct 27, 2026 | total revenue | FY2026 | $124.00M – $126.00M | Lowered |
| Jul 29, 2026 | gross margin | FY2026 | 58.5% – 59.5% | Raised |
| Jul 29, 2026 | new patient starts reimbursed through the PBP channel | FY2026 | 37% – 39% | Reaffirmed |
| Jul 29, 2026 | total revenue | FY2026 | $131.00M – $136.00M | Reaffirmed |
| Apr 21, 2026 | gross margin | FY2026 | 57.5% – 59.5% | New |
| Apr 21, 2026 | new patient starts reimbursed through the PBP channel | FY2026 | 37% – 39% | New |
| Apr 21, 2026 | total revenue | FY2026 | $131.00M – $136.00M | New |
| Feb 17, 2026 | gross margin | FY2026 | 55.5% – 57.5% | New |
| Feb 17, 2026 | new patient starts reimbursed through the PBP channel | FY2026 | 36% – 38% | New |
| Feb 17, 2026 | total revenue | FY2026 | $130.00M – $135.00M | New |
| Oct 28, 2025 | gross margin | FY2025 | 54% – 55% | New |
| Oct 28, 2025 | new patient starts reimbursed through the PBP channel | FY2025 | 27% – 29% | New |
| Oct 28, 2025 | total revenue | FY2025 | $96.50M | New |
| Jul 29, 2025 | gross margin | FY2025 | 52% – 55% | Raised |
| Jul 29, 2025 | percentage of new patient starts reimbursed through the PBP channel | FY2025 | 25% – 28% | Raised |
| Jul 29, 2025 | total revenue | FY2025 | $88.00M – $93.00M | Raised |
| May 6, 2025 | gross margin | FY2025 | 50% – 53% | Raised |
| May 6, 2025 | percentage of new patient starts reimbursed through the PBP channel | FY2025 | 22% – 25% | Raised |
| May 6, 2025 | total revenue | FY2025 | $82.00M – $87.00M | Raised |
| Mar 25, 2025 | gross margin | FY2025 | 50% | New |
| Mar 25, 2025 | new patient starts reimbursed through the PBP channel | FY2025 | 20% | New |
| Mar 25, 2025 | total revenue | FY2025 | $80.00M – $85.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Beta Bionics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Update
- Update
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
See a number that looks wrong?